Compare GSK plc (GSK) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Trip.com Group Ltd — how do they compare? GSK plc trades at $46.83 (market cap $95.18B), while Trip.com Group Ltd trades at $38.62 (market cap $24.30B). The key difference: GSK plc is far larger — about 3.9× Trip.com Group Ltd's market cap, and GSK plc pays the higher dividend (3.86%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Trip.com Group Ltd for 79 Days on average.
| GSK | TCOM | |
|---|---|---|
Market Cap | $95.18B | $24.30B |
Volume | 5,852,596 | 1,885,560 |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $78.96 |
52-Week Low | $43.24 | $37.96 |
Typical Hold Time | 93 Days | 79 Days |
Enterprise Value | $115.25B | $16.46B |
Dividend Yield | 3.86% | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 0.13% with a bearish technical signal. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 15.1 and EV/EBITDA of 9.0. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for growth beyond upcoming HIV patent expirations.
GSK presents a balanced investment case with solid profitability (29.7% ROE) offset by near-term headwinds. The stock offers value at current levels but faces execution risks from pipeline development and patent cliffs. Analyst sentiment leans cautious with 55% hold ratings, suggesting moderate upside potential with careful risk management required.
Trip.com (TCOM) trades at $37.96, down 0.78% on the day, amid a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 36.9% net income margin and trades at a low P/E of 7.36. Recent Q2 2026 earnings beat expectations, yet regulatory pressures and a challenging travel environment create headwinds. Analyst consensus remains strongly bullish with a $56.64 price target, indicating significant upside potential from current levels.
The outlook for TCOM balances strong earnings growth and attractive valuation against regulatory risks and market volatility. Investment opportunity lies in its dominant travel platform and international expansion, but investors face risks from antitrust penalties and competitive pressures. The stock's current discount to analyst targets presents a potential value opportunity if execution remains solid.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
